Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus
Identifieur interne : 004102 ( Main/Exploration ); précédent : 004101; suivant : 004103Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus
Auteurs : Sang-Gug Kim [Japon] ; Toshifumi Hatta [Japon] ; Satoru Tsukahara [Japon] ; Hideki Nakashima [Japon] ; Naoki Yamamoto [Japon] ; Yoko Shoji [Japon] ; Kazuyuki Takai [Japon] ; Hiroshi Takaku [Japon]Source :
- Bioorganic & Medicinal Chemistry [ 0968-0896 ] ; 1995.
Descripteurs français
- KwdFr :
- ADN viral, Antiviraux (pharmacologie), Antiviraux (synthèse chimique), Ciblage de gène, Données de séquences moléculaires, Humains, Lignée cellulaire, Oligonucléotides antisens (pharmacologie), Oligonucléotides antisens (synthèse chimique), Réplication virale (), Séquence nucléotidique, Thionucléotides (pharmacologie), Thionucléotides (synthèse chimique), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (physiologie).
- MESH :
- pharmacologie : Antiviraux, Oligonucléotides antisens, Thionucléotides.
- physiologie : VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- synthèse chimique : Antiviraux, Oligonucléotides antisens, Thionucléotides.
- ADN viral, Ciblage de gène, Données de séquences moléculaires, Humains, Lignée cellulaire, Réplication virale, Séquence nucléotidique, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
English descriptors
- KwdEn :
- Antiviral Agents (chemical synthesis), Antiviral Agents (pharmacology), Base Sequence, Cell Line, DNA, Viral, Gene Targeting, HIV-1 (drug effects), HIV-1 (physiology), Humans, Molecular Sequence Data, Oligonucleotides, Antisense (chemical synthesis), Oligonucleotides, Antisense (pharmacology), Thionucleotides (chemical synthesis), Thionucleotides (pharmacology), Virus Replication (drug effects).
- MESH :
- chemical , chemical synthesis : Antiviral Agents, Oligonucleotides, Antisense, Thionucleotides.
- chemical , pharmacology : Antiviral Agents, Oligonucleotides, Antisense, Thionucleotides.
- drug effects : HIV-1, Virus Replication.
- physiology : HIV-1.
- Teeft :
- Acad, Acceptor, Antisense, Antisense oligomers, Antisense oligonucleotides, Antisense sequences, Antiviral effect, Base Sequence, Cell Line, Cellular uptake, Chain length, Chain lengths, Chiba institute, Culture medium, DNA, Viral, Different target sites, Gene Targeting, Human immunodeficiency virus, Humans, Inhibitory effect, Initiator codon, Molecular Sequence Data, Mrna processing, Nail acad, Natl, Natl acad, Nucleic acids, Oligomer, Oligomers, Oligonucleotide, Oligonucleotides, Other hand, Particular interest, Phosphorothioate, Phosphorothioate group, Phosphorothioate groups, Phosphorothioate oligodeoxyribonucleotides, Phosphorothioate oligomer, Phosphorothioate oligomers, Phosphorothioate oligonucleotide analogues, Phosphorothioate oligonucleotides, Proc, Random sequence, Replication, Sense sequence, Soodns oligomer, Splice, Splice acceptor, Splice acceptor sites, Target sequences, Target site, Test compounds, Viral, Viral expression, Viral replication.
Abstract
Abstract: Modifications of oligodeoxyribonucleotides include the replacement of the backbone phosphodiester groups with phosphorothioate (S-ODNs) groups and the substitution of phosphorothioate (SO-ODNs) groups at both the 3′- and 5′-ends. In assays for HIV, oligomers (S-ODNs) were more active at the micromolar range than were SO-ODNs of the same sequence. Furthermore, the abilities of antisense-, sense-, random-, and mismatched-oligomers, or homo-oligomers containing internucleotidic phosphorothioate linkages to inhibit HIV-1 replication were examined. Antisense oligonucleotides inhibit the replication and the expression of HIV-1 more efficiently than random-, sense-, mismatched-, and homo-oligomers of the same length or with the same internucleotide modification. Five different target sites (gag, pol, rev, tat, and tar) within the HIV genes were also studied with regard to the inhibition of HIV replication by antisense oligonucleotides. Antisense oligomers complementary to the sites of initiation sequences and to certain splice sites were most effective. The effect of antisense oligomer length on inhibiting viral replication was also investigated. Of particular interest was the S-ODNs-rev 15 mer, which possessed higher anti-HIV activity than the sense-, random-, mismatched-, and homo-20 mers.
Url:
DOI: 10.1016/0968-0896(94)00142-P
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000215
- to stream Istex, to step Curation: 000215
- to stream Istex, to step Checkpoint: 001793
- to stream Main, to step Merge: 004163
- to stream PubMed, to step Corpus: 002840
- to stream PubMed, to step Curation: 002840
- to stream PubMed, to step Checkpoint: 002695
- to stream Ncbi, to step Merge: 002A13
- to stream Ncbi, to step Curation: 002A13
- to stream Ncbi, to step Checkpoint: 002A13
- to stream Main, to step Merge: 004115
- to stream Main, to step Curation: 004102
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus</title><author><name sortKey="Kim, Sang Gug" sort="Kim, Sang Gug" uniqKey="Kim S" first="Sang-Gug" last="Kim">Sang-Gug Kim</name></author><author><name sortKey="Hatta, Toshifumi" sort="Hatta, Toshifumi" uniqKey="Hatta T" first="Toshifumi" last="Hatta">Toshifumi Hatta</name></author><author><name sortKey="Tsukahara, Satoru" sort="Tsukahara, Satoru" uniqKey="Tsukahara S" first="Satoru" last="Tsukahara">Satoru Tsukahara</name></author><author><name sortKey="Nakashima, Hideki" sort="Nakashima, Hideki" uniqKey="Nakashima H" first="Hideki" last="Nakashima">Hideki Nakashima</name></author><author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name></author><author><name sortKey="Shoji, Yoko" sort="Shoji, Yoko" uniqKey="Shoji Y" first="Yoko" last="Shoji">Yoko Shoji</name></author><author><name sortKey="Takai, Kazuyuki" sort="Takai, Kazuyuki" uniqKey="Takai K" first="Kazuyuki" last="Takai">Kazuyuki Takai</name></author><author><name sortKey="Takaku, Hiroshi" sort="Takaku, Hiroshi" uniqKey="Takaku H" first="Hiroshi" last="Takaku">Hiroshi Takaku</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5107325DD02376C0857BDB142DAAD066D2A94220</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0968-0896(94)00142-P</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-V2K7H0H7-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000215</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000215</idno><idno type="wicri:Area/Istex/Curation">000215</idno><idno type="wicri:Area/Istex/Checkpoint">001793</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001793</idno><idno type="wicri:doubleKey">0968-0896:1995:Kim S:antiviral:effect:of</idno><idno type="wicri:Area/Main/Merge">004163</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8612046</idno><idno type="wicri:Area/PubMed/Corpus">002840</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002840</idno><idno type="wicri:Area/PubMed/Curation">002840</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002840</idno><idno type="wicri:Area/PubMed/Checkpoint">002695</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002695</idno><idno type="wicri:Area/Ncbi/Merge">002A13</idno><idno type="wicri:Area/Ncbi/Curation">002A13</idno><idno type="wicri:Area/Ncbi/Checkpoint">002A13</idno><idno type="wicri:doubleKey">0968-0896:1995:Kim S:antiviral:effect:of</idno><idno type="wicri:Area/Main/Merge">004115</idno><idno type="wicri:Area/Main/Curation">004102</idno><idno type="wicri:Area/Main/Exploration">004102</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus</title><author><name sortKey="Kim, Sang Gug" sort="Kim, Sang Gug" uniqKey="Kim S" first="Sang-Gug" last="Kim">Sang-Gug Kim</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Industrial Chemistry, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba 275</wicri:regionArea><wicri:noRegion>Chiba 275</wicri:noRegion></affiliation></author><author><name sortKey="Hatta, Toshifumi" sort="Hatta, Toshifumi" uniqKey="Hatta T" first="Toshifumi" last="Hatta">Toshifumi Hatta</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Industrial Chemistry, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba 275</wicri:regionArea><wicri:noRegion>Chiba 275</wicri:noRegion></affiliation></author><author><name sortKey="Tsukahara, Satoru" sort="Tsukahara, Satoru" uniqKey="Tsukahara S" first="Satoru" last="Tsukahara">Satoru Tsukahara</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Industrial Chemistry, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba 275</wicri:regionArea><wicri:noRegion>Chiba 275</wicri:noRegion></affiliation></author><author><name sortKey="Nakashima, Hideki" sort="Nakashima, Hideki" uniqKey="Nakashima H" first="Hideki" last="Nakashima">Hideki Nakashima</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Microbiology, Tokyo Medical and Dental University School of Medicine, Yushima, Bunkyo-ku, Tokyo 113</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Microbiology, Tokyo Medical and Dental University School of Medicine, Yushima, Bunkyo-ku, Tokyo 113</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Shoji, Yoko" sort="Shoji, Yoko" uniqKey="Shoji Y" first="Yoko" last="Shoji">Yoko Shoji</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Institute of Medical Science, ST. Marianna University School of Medicine, Sugao, Miyamae-ku, Kawasaki, Kanagawa 261</wicri:regionArea><wicri:noRegion>Kanagawa 261</wicri:noRegion></affiliation></author><author><name sortKey="Takai, Kazuyuki" sort="Takai, Kazuyuki" uniqKey="Takai K" first="Kazuyuki" last="Takai">Kazuyuki Takai</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Industrial Chemistry, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba 275</wicri:regionArea><wicri:noRegion>Chiba 275</wicri:noRegion></affiliation></author><author><name sortKey="Takaku, Hiroshi" sort="Takaku, Hiroshi" uniqKey="Takaku H" first="Hiroshi" last="Takaku">Hiroshi Takaku</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Industrial Chemistry, Chiba Institute of Technology, Tsudanuma, Narashino, Chiba 275</wicri:regionArea><wicri:noRegion>Chiba 275</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Bioorganic & Medicinal Chemistry</title><title level="j" type="abbrev">BMC</title><idno type="ISSN">0968-0896</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">3</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="49">49</biblScope><biblScope unit="page" to="54">54</biblScope></imprint><idno type="ISSN">0968-0896</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0968-0896</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (chemical synthesis)</term><term>Antiviral Agents (pharmacology)</term><term>Base Sequence</term><term>Cell Line</term><term>DNA, Viral</term><term>Gene Targeting</term><term>HIV-1 (drug effects)</term><term>HIV-1 (physiology)</term><term>Humans</term><term>Molecular Sequence Data</term><term>Oligonucleotides, Antisense (chemical synthesis)</term><term>Oligonucleotides, Antisense (pharmacology)</term><term>Thionucleotides (chemical synthesis)</term><term>Thionucleotides (pharmacology)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (synthèse chimique)</term><term>Ciblage de gène</term><term>Données de séquences moléculaires</term><term>Humains</term><term>Lignée cellulaire</term><term>Oligonucléotides antisens (pharmacologie)</term><term>Oligonucléotides antisens (synthèse chimique)</term><term>Réplication virale ()</term><term>Séquence nucléotidique</term><term>Thionucléotides (pharmacologie)</term><term>Thionucléotides (synthèse chimique)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Antiviral Agents</term><term>Oligonucleotides, Antisense</term><term>Thionucleotides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Oligonucleotides, Antisense</term><term>Thionucleotides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Oligonucléotides antisens</term><term>Thionucléotides</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Antiviraux</term><term>Oligonucléotides antisens</term><term>Thionucléotides</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Acceptor</term><term>Antisense</term><term>Antisense oligomers</term><term>Antisense oligonucleotides</term><term>Antisense sequences</term><term>Antiviral effect</term><term>Base Sequence</term><term>Cell Line</term><term>Cellular uptake</term><term>Chain length</term><term>Chain lengths</term><term>Chiba institute</term><term>Culture medium</term><term>DNA, Viral</term><term>Different target sites</term><term>Gene Targeting</term><term>Human immunodeficiency virus</term><term>Humans</term><term>Inhibitory effect</term><term>Initiator codon</term><term>Molecular Sequence Data</term><term>Mrna processing</term><term>Nail acad</term><term>Natl</term><term>Natl acad</term><term>Nucleic acids</term><term>Oligomer</term><term>Oligomers</term><term>Oligonucleotide</term><term>Oligonucleotides</term><term>Other hand</term><term>Particular interest</term><term>Phosphorothioate</term><term>Phosphorothioate group</term><term>Phosphorothioate groups</term><term>Phosphorothioate oligodeoxyribonucleotides</term><term>Phosphorothioate oligomer</term><term>Phosphorothioate oligomers</term><term>Phosphorothioate oligonucleotide analogues</term><term>Phosphorothioate oligonucleotides</term><term>Proc</term><term>Random sequence</term><term>Replication</term><term>Sense sequence</term><term>Soodns oligomer</term><term>Splice</term><term>Splice acceptor</term><term>Splice acceptor sites</term><term>Target sequences</term><term>Target site</term><term>Test compounds</term><term>Viral</term><term>Viral expression</term><term>Viral replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>ADN viral</term><term>Ciblage de gène</term><term>Données de séquences moléculaires</term><term>Humains</term><term>Lignée cellulaire</term><term>Réplication virale</term><term>Séquence nucléotidique</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Modifications of oligodeoxyribonucleotides include the replacement of the backbone phosphodiester groups with phosphorothioate (S-ODNs) groups and the substitution of phosphorothioate (SO-ODNs) groups at both the 3′- and 5′-ends. In assays for HIV, oligomers (S-ODNs) were more active at the micromolar range than were SO-ODNs of the same sequence. Furthermore, the abilities of antisense-, sense-, random-, and mismatched-oligomers, or homo-oligomers containing internucleotidic phosphorothioate linkages to inhibit HIV-1 replication were examined. Antisense oligonucleotides inhibit the replication and the expression of HIV-1 more efficiently than random-, sense-, mismatched-, and homo-oligomers of the same length or with the same internucleotide modification. Five different target sites (gag, pol, rev, tat, and tar) within the HIV genes were also studied with regard to the inhibition of HIV replication by antisense oligonucleotides. Antisense oligomers complementary to the sites of initiation sequences and to certain splice sites were most effective. The effect of antisense oligomer length on inhibiting viral replication was also investigated. Of particular interest was the S-ODNs-rev 15 mer, which possessed higher anti-HIV activity than the sense-, random-, mismatched-, and homo-20 mers.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><country name="Japon"><noRegion><name sortKey="Kim, Sang Gug" sort="Kim, Sang Gug" uniqKey="Kim S" first="Sang-Gug" last="Kim">Sang-Gug Kim</name></noRegion><name sortKey="Hatta, Toshifumi" sort="Hatta, Toshifumi" uniqKey="Hatta T" first="Toshifumi" last="Hatta">Toshifumi Hatta</name><name sortKey="Nakashima, Hideki" sort="Nakashima, Hideki" uniqKey="Nakashima H" first="Hideki" last="Nakashima">Hideki Nakashima</name><name sortKey="Shoji, Yoko" sort="Shoji, Yoko" uniqKey="Shoji Y" first="Yoko" last="Shoji">Yoko Shoji</name><name sortKey="Takai, Kazuyuki" sort="Takai, Kazuyuki" uniqKey="Takai K" first="Kazuyuki" last="Takai">Kazuyuki Takai</name><name sortKey="Takaku, Hiroshi" sort="Takaku, Hiroshi" uniqKey="Takaku H" first="Hiroshi" last="Takaku">Hiroshi Takaku</name><name sortKey="Tsukahara, Satoru" sort="Tsukahara, Satoru" uniqKey="Tsukahara S" first="Satoru" last="Tsukahara">Satoru Tsukahara</name><name sortKey="Yamamoto, Naoki" sort="Yamamoto, Naoki" uniqKey="Yamamoto N" first="Naoki" last="Yamamoto">Naoki Yamamoto</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004102 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004102 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5107325DD02376C0857BDB142DAAD066D2A94220
|texte= Antiviral effect of phosphorothioate oligodeoxyribonucleotides complementary to human immunodeficiency virus
}}
| This area was generated with Dilib version V0.6.33. |  |